Single Gene Therapy Injection Cuts LDL Cholesterol by 62% in Early Trial
VERVE-102 permanently silences the PCSK9 gene in a single dose, slashing LDL cholesterol up to 62% with encouraging early safety data.
Summary
A one-time gene-editing therapy called VERVE-102 may permanently lower LDL cholesterol by silencing the PCSK9 gene in the liver. In a phase Ib trial involving patients with inherited high cholesterol or early heart disease, a single infusion reduced LDL by up to 62% and PCSK9 levels by up to 88%. Results appeared durable at one year of follow-up. Unlike daily statins or regular injections, this approach aims to be a permanent fix. The therapy uses a lipid nanoparticle delivery system redesigned to improve safety over its predecessor. No dose-limiting toxicities were observed, though mild infusion reactions and temporary liver enzyme elevations occurred. Results were published in the New England Journal of Medicine.
Detailed Summary
High LDL cholesterol remains one of the most powerful risk factors for cardiovascular disease, yet millions of people worldwide fail to achieve recommended targets due to medication side effects, cost, or simple non-adherence to daily pills. A one-time gene therapy could change that equation entirely, and early results from a clinical trial are offering cautious optimism.
VERVE-102 is a base-editing gene therapy designed to permanently switch off the PCSK9 gene inside liver cells. PCSK9 is a protein that degrades LDL receptors — by silencing the gene, more LDL receptors remain active, pulling more LDL cholesterol out of the bloodstream. In the Heart-2 phase Ib trial, a single infusion reduced PCSK9 levels by 51–88% and LDL cholesterol by 9–62% depending on dose, with an absolute drop of 78 mg/dL at the highest dose tested.
Critically, the reductions appeared durable. Among 15 participants with at least one year of follow-up, the effects held. This sustained benefit distinguishes gene therapy from the ongoing burden of daily statins or bi-weekly PCSK9 inhibitor injections, both of which depend on consistent patient adherence.
The safety profile represents a meaningful improvement over VERVE-101, its predecessor, which was discontinued after causing elevated liver enzymes and reduced platelet counts. VERVE-102 uses a redesigned lipid nanoparticle delivery system incorporating a GalNAc-targeting ligand to improve liver specificity. No dose-limiting toxicities were recorded in this interim analysis, though mild infusion reactions and transient ALT elevations were observed.
This is still early-phase data in a small, selected patient population. Larger trials will be needed to confirm long-term safety and efficacy, determine optimal dosing, and assess whether effects remain permanent over many years. Nevertheless, for cardiovascular disease prevention, a one-time LDL-lowering intervention represents a potentially transformative therapeutic direction.
Key Findings
- Single VERVE-102 infusion reduced LDL cholesterol by up to 62% and PCSK9 by up to 88% across doses.
- LDL reductions appeared durable at one year of follow-up in 15 participants.
- Absolute LDL drop of 78 mg/dL achieved at the highest dose of 1.0 mg/kg.
- Redesigned lipid nanoparticle delivery system showed no dose-limiting toxicities in this interim analysis.
- One-time gene silencing could replace chronic statin or PCSK9 inhibitor therapy for high-risk patients.
Methodology
This is a news report summarizing an interim analysis of the Heart-2 phase Ib clinical trial, published in the New England Journal of Medicine and presented at the European Atherosclerosis Society Congress. The source, MedPage Today, is a credible medical journalism outlet. Evidence is based on early-phase human trial data with limited sample size and follow-up duration.
Study Limitations
This is interim phase Ib data from a small trial, meaning sample sizes are too limited to draw definitive conclusions about long-term safety or efficacy. The 1-year durability data covers only 15 participants, and it remains unknown whether gene silencing persists over decades. Independent replication in larger, more diverse populations is needed before clinical adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.